Table 1.
Demographic, clinical, and pathological characteristics of patients by serum cholesterol status
| Cholesterol < 200 mg/dl (n=518; 61%) | Cholesterol ≥ 200 mg/dl (n=325; 39%) | p-value | |
|---|---|---|---|
|
|
|||
| Age, mean ± SD | 60.4 ± 6.3 | 60.6 ± 6.4 | 0.664‡ |
| Race, n (%) | 0.106§ | ||
| Black | 222 (43) | 121 (37) | |
| Non-black | 296 (57) | 204 (63) | |
| Year of surgery, median (Q1–Q3) | 2005 (2003, 2008) | 2004 (2002, 2007) | <0.001† |
| Follow-up, median (Q1–Q3) | 74.7 (41.3, 99.0) | 73.4 (41.5, 108.1) | 0.501† |
| PSA, median (Q1–Q3) | 6.3 (4.8, 9.4) | 7.2 (5.0, 10.5) | 0.071† |
| Statin use, n (%) | <0.001§ | ||
| Never | 308 (59) | 108 (33) | |
| Started after RP | 210 (41) | 217 (67) | |
| BMI, median (Q1–Q3) | 27.4 (24.7, 30.5) | 27.5 (24.9, 30.6) | 0.936† |
| Diabetes, n (%) | 84 (21) | 48 (20) | 0.687† |
| LDL, mean (SD) | 101.9 (21.6) | 141.9 (25.4) | <0.0001 |
| HDL, mean (SD) | 43.8 (13.7) | 51.2 (20.3) | <0.0001 |
| Triglycerides, mean (SD) | 126.0 (83.2) | 150.0 (83.9) | 0.0001 |
| Pathological Gleason score, n (%) | 0.276§ | ||
| 2–6 | 177 (34) | 125 (39) | |
| 7 (3+4) | 214 (41) | 134 (41) | |
| 7 (4+3)–10 | 127 (25) | 66 (20) | |
| Positive margins, n (%) | 228 (44) | 141 (43) | 0.857† |
| Extracapsular extension, n (%) | 87 (17) | 66 (20) | 0.198† |
| Seminal vesicle invasion, n (%) | 44 (8) | 30 (9) | 0.713† |
| Positive lymph nodes, n (%) | 12 (2) | 9 (3) | 0.919† |
SD=standard deviation; Q1=25th percentile; Q3=75th percentile; PSA=prostate specific antigen; BMI=body mass index; RP=radical prostatectomy
p values calculated by
‡
t-test,
†
Wilcoxon rank-sum or
§
chi-square test